Jorga K, Buss NE; Interscience Conference on Antimicrobial Agents and Chemotherapy.
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1999 Sep 26-29; 39: 20 (abstract no. 339).
F. Hoffmann-La Roche Ltd., Basel, Switzerland
BACKGROUND: Saquinavir (SQV) is a substrate as well as an inhibitor of cytochrome P450 3A and therefore has potential for drug-drug interactions.METHODS: A retrospective review was conducted of PK data from studies of co-administered SQV-soft gelatin capsule (SQV-SGC; Fortovase>) in HIV-infected individuals and healthy adults.RESULTS: Peak plasma concentration (C[max]) and area under plasma concentration-time curve (AUC) values for SQV-SGC and co-prescribed drugs (determined under steady-state conditions unless otherwise specified) are summarized in the table below. [table: see text]CONCLUSIONS: SQV exposure was reduced by EFV, RFB and RFP, but increased 2-5-fold by IDV, NFV, Clar and Keto, and up to 20-fold by RTV. SQV-SGC had minimal effect on the PKs of co-administered drugs, apart from terfenadine. Accordingly, co-administration of terfenadine and SQV-SGC is contraindicated.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Adult
- Area Under Curve
- Capsules
- Drug Interactions
- Gelatin
- HIV Infections
- HIV Seropositivity
- Humans
- Saquinavir
- Terfenadine
- pharmacokinetics
Other ID:
UI: 102244678
From Meeting Abstracts